Heterocyclyls as selective melanin concentrating hormone...

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C548S131000, C548S204000, C548S236000, C548S255000, C548S267600, C548S338100, C548S375100, C548S561000, C549S076000, C549S496000

Reexamination Certificate

active

11181255

ABSTRACT:
The present invention discloses compounds of formula Iwherein m, n, p, R1, R2and X, are herein defined, the compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

REFERENCES:
patent: 2001/0049373 (2001-12-01), Chalquest
Sawa, et al.; Recent developments in the design of orally bioavailable beta3-adrenergic receptor agonists. 2006; Current Medicinal Chemistry; 13, 25-37.
Orbach, S; Drug-drug interactions: an important negative attribute in drugs. 2003, Drugs of Today, 39, 301-338.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Heterocyclyls as selective melanin concentrating hormone... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclyls as selective melanin concentrating hormone..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclyls as selective melanin concentrating hormone... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3916522

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.